Keywords
cardiovascular diseases
low-density lipoprotein cholesterol
statins
ezetimibe
PCSK9 inhibitors
bempedic acid
How to Cite
Abstract
Aim. To summarize scientific publications, clinical guidelines (CG) regarding the development of standardized approaches to the correction of dyslipidemia and the introduction of new hypolipidemic drugs at the current stage.
Materials and methods. The analysis and generalization of scientific articles, clinical guidelines on the introduction of standardized approaches to the correction of dyslipidemia at the current stage and the use of new hypolipidemic drugs for the prevention and treatment of cardiovascular diseases (CVD) were carried out. Methods were used: systematic approach, bibliosemantic, analytical.
Results. Modern standardized approaches to the appointment of hypolipidemic therapy for the primary and secondary prevention of atherosclerotic CVD are based on the definition of the general cardiovascular risk, which is regulated by CG. Meta-analyses of clinical trials have shown that the relative reduction of CVD risk is proportional to the absolute reduction in low-density lipoprotein cholesterol levels, regardless of the drug(s) used. Statins remain the drugs of the first line of hypolipidemic therapy. In accordance with modern clinical practice, it is recommended to prescribe statins in maximum tolerated doses and use combined therapy with new hypolipidemic drugs when the target level of indicators is not reached. Combinations with statins start with ezetimibe, in case of insufficient efficacy, it is recommended to add a PCSK9 inhibitor (evolocumab, alirocumab, incliziran). Wider use of PCSK9 inhibitors is limited by the high cost of drugs of this group. CG 2023 and 2024 recommend the use of another new drug – bempedic acid – in clinical practice for the correction of dyslipidemia.
Conclusions. The introduction of modern approaches, in particular regarding the combination of hypolipidemic therapy drugs, which are adapted to each clinical case, provide new opportunities for primary and secondary prevention of CVD, which requires additional funds of the health care system.
References
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) (2020) European Heart Journal, 41, 111-188. Doi:10.1093/eurheartj/ehz455
2018АHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines (2019). J Am Coll Cardiol, 73(24), 3168-3209. Doi: 10.1016/j.jacc.2018.11.002.
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults (2021). Can J Cardiol., 37(8), 1129-1150. https://onlinecjc.ca/article/S0828-282X(21)00165-3/fulltext
Grundy, S M., & Feingold, K R. (2022). Guidelines for the Management of High Blood Cholesterol. https://www.ncbi.nlm.nih.gov/books/NBK305897/
Talwalkar P. G., Sreenivas C. G., Gulati A., & Baxi H.(2013). Journey in guidelines for lipid management: From adult treatment panel (ATP)‑I to ATP‑III and what to expect in ATP‑IV. Indian J Endocrinol Metab. 17(4), 628-35. Doi: 10.4103/2230-8210.113753.
Guasti, L, & Lupi, A. (2024). Lipidology update: targets and timing of well-established therapies https://www.escardio.org/Councils/Council-for-Cardiology-Practice-(CCP)/Cardiopractice/lipidology-update-targets-and-timing-of-well-established-therapies
The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014). Circulation, 129 (25 Suppl 2), S1-45. Doi: 10.1161/01.cir.0000437738.63853.7a
2011 ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) (2011) Eur Heart J, 32(14), 1769-818. Doi: 10.1093/eurheartj/ehr158
Reiner, Z. (2011). New ESC/EAS Guidelines for the management of dyslipidaemias – any controversies behind the consensus? Eur J Cardiovas Prev Rehab, 18(5), 724–727. Doi: 10.1177/1741826711418946
Ray, KK, Kastelein, JJ, Boekholdt, SM, Nicholls, SJ, Khaw, KT, Ballantyne, CM, Catapano, AL, Reiner, Ž, & Lüscher, TF. (2014). The ACC/AHA 2013 guideline on the treatment of blood chole sterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J., 35(15), 960-8. Doi: 10.1093/eurheartj/ehu107.
2016 ESC/EAS Guidelines for the management of dyslipidaemias (2016). Eur Heart J, 37(39), 2999-3058. Doi: 10.1093/eurheartj/ehw272
Şimşek, B, İnan, D, Çınar, T, Cagdas-Yumurtaş, A, Ozan-Tanık, V, Zeren, G, İlker-Avcı, İ, Yücel-Karabay, C, Güngör, B, & Tokgozoğlu, L. (2021). Evaluation of Low-density Lipoprotein Cholesterol Target Attainment Rates According to the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines for Secondary Prevention in Patients with Acute Myocardial Infarction. Rev Invest Clin., 73(3), 371-378. Doi: 10.24875/RIC.21000152
Drexel, H. (2017). A commentary on the new ESC guidelines on Dyslipidaemias. European Heart Journal – Cardiovascular Pharmacotherapy 3, 73–74. Doi:10.1093/ehjcvp/pvx001
Pandor, A, Ara, RM, Tumur, I, Wilkinson, AJ, Paisley, S, Duenas, A, Durrington, PN, Chilcott, J. (2009). Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med, 265, 568–580 doi: 10.1111/j.1365-2796.2008.02062.x.
Morrone, D, Weintraub, WS, Toth, PP, Hanson, ME, Lowe, RS, Lin, J, Shah, AK, & Tershakovec, AM. (2012). Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis, 223, 251-261. Doi: 10.1016/j.atherosclerosis.2012.02.016
de Isla, P. L, Liberopoulos, E, Dovizio, M, Veronesi, C, Esposti, L D., & Zambon, A (2024). Differential Adherence to Free and Single-Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real-World Analysis in Italy. Adv Ther., 41(8), 3407-3418. Doi: 10.1007/s12325-024-02916-8
Ferri, N., Ruscica, M., Fazio, S., & Corsini, А. (2024). A. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review. J. Clin. Med. 13: 943. Doi: 10.3390/jcm13040943
Gallego-Colon, E, Daum, A, & Yosefy, C. (2020). Eur Statins and PCSK9 inhibitors: A new lipid-lowering therapy. J Pharmacol. 878, 173114. Doi: 10.1016/j.ejphar.2020.173114
Rached, F, & Santos, RD (2021). Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias. Curr Cardiol Rep. 23(7), 83. Doi: 10.1007/s11886-021-01514-2
Michaeli, DT, Michaeli, JC, Albers, S, Boch, T, & Michaeli, T (2023). Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention..Am J Cardiovasc Drugs, ;23(5), 477-495. Doi: 10.1007/s40256-023-00594-5
Hajar, R. (2019). PCSK 9 Inhibitors: A Short History and a New Era of Lipid-lowering Therapy. Heart Views, 20(2), 74-75. Doi: 10.4103/HEARTVIEWS.HEARTVIEWS_59_19
de Oliveira, L.L.H., de Assis, A.C.R., Giraldez, V.Z.R., Scudeler, T.L,. & Soares, P.R. (2024). Dyslipidemia: A Narrative Review on Pharmacotherapy. Pharmaceuticals, 17, 289. https://doi.org/ 10.3390/ph17030289
Kaddoura, R, Orabi, B, & Salam, AM.(2020). PCSK9 Monoclonal Antibodies: An Overview. Heart Views, 21(2), 97-103. Doi: 10.4103/HEARTVIEWS.HEARTVIEWS_20_20
Jain P. (2024). Traditional and novel non-statin lipid-lowering drugs. Indian Heart J., 76 (Suppl 1), S38-S43. Doi: 10.1016/j.ihj.2023.11.003
Warden, BA, & Duell, PB. (2021). Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. J Cardiovasc Pharmacol., 78(2), e157-e174. Doi: 10.1097/FJC.0000000000001053
Di Fusco, SA, Maggioni, AP, Bernelli, C, Perone, F, De Marzo. V, Conte. E, Musella, F, Uccello, G, Luca, L, Gabrielli, D, Gulizia, MM, Oliva, F, & Colivicchi, F. (2022). Inclisiran: A New Pharmacological Approach for Hypercholesterolemia. Rev Cardiovasc Med. 23(11), 375. Doi: 10.31083/j.rcm2311375.
Wright R. S., Koenig,W., Landmesser,U., Leiter L. A., Raal F. J., Schwartz, G.G., Lesogor, A., Maheux P., Stratz, C.,, Zang X.,& Kausik K. Ray K.K. (2023). Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials. J Am Coll Cardiol., 82 (24), 2251–2261.
Raal F. J., Kallend D., M.B., B.S., Ray K. K., Turner T., Koenig W., Wright R. S., Wijngaard P. L.J., Curcio D., Jaros M.J., Leiter L. A., & Kastelein J. J.P. for the ORION-9 Investigators (2020). Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med, 382 (16), 1520-1530. DOI: 10.1056/NEJMoa1913805
Ray, KK, Wright, RS, Kallend, D, Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J.A. Richardson, T., Jaros, M.J., Wijngaard P. L.J & Kastelein J. J.P. for the ORION-10 and ORION-11 Investigators (2020). Two Phase 3 Trials of Inclisiran in Patients With Elevated LDL Cholesterol. N Engl J Med, 38, 1507-19 doi: 10.1056/NEJMoa1912387.
Raal F, Durst R, Bi R, Talloczy, Z, Maheux P., Lesogor, A., & Kastelein J. J.P.: ORION-5 Study Investigators (2024). Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Circulation, 149, 354-62. Doi: 10.1161/CIRCULATIONAHA.122.063460.
Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias. (2020). Rev Esp Cardiol., 73(5), 348–353. Doi.10.1016/j.rec.2019.11.019
Biolo, G, Vinci, P, Mangogna, A, Landolfo, M, Schincariol, P, Fiotti, N, Mearelli, F, & Di Girolamo, FG. (2022). Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome. Front Cardiovasc Med., 9:1028355. Doi: 10.3389/fcvm.2022.1028355
Ferri N, Ruscica M, Santos RD, & Corsini A.(2023). Fixed Combination for the Treatment of Dyslipidaemia. Curr Atheroscler Rep., 25(10), 691-699. Doi: 10.1007/s11883-023-01142-x
Kim K, Ginsberg HN, & Choi SH. (2022). New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. Diabetes Metab J., 46(5), 517-532. Doi: 10.4093/dmj.2022.0198
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines (2023). Circulation, 148, e9–e119. DOI: 10.1161/CIR.0000000000001168
2024 ESC Guidelines for the management of chronic coronary syndromes (2024). Eur. Heart J., ehae177, 1–123. Doi.10.1093/eurheartj/ehae177
Khan, Z, Gul, A, Yousif, Y, & Gupta, A. A. (2023). Systematic Review of Lipid Management in Secondary Prevention and Comparison of International Lipid Management Pathways Cureus., 15(2), e35463. Doi: 10.7759/cureus.35463
Katzmann, JL, Stürzebecher, PE, Kruppert, S, & Laufs, U. LDL cholesterol target attainment in cardiovascular high- and very-high-risk patients with statin intolerance: a simulation study. Sci Rep., 14(1), 474. Doi: 10.1038/s41598-023-50847-1.
Schiele, F, Catapano, AL, De Caterina, R, Laufs, U, Jukema, JW, Zaman, A, & Sionis, A. (2024). Quality control to improve LDL-cholesterol management in patients with acute coronary syndromes based on the ACS EuroPath IV project. Eur Heart J Acute Cardiovasc Care. 13(1), 46-54. Doi: 10.1093/ehjacc/zuad119
Aygun, S, & Tokgozoglu, L. (2022). Comparison of Current International Guidelines for the Management of Dyslipidemia. J Clin Med., 11(23), 7249. Doi: 10.3390/jcm11237249.
Laufs, U., Catapano, A.L., De Caterina, R., Schiele, F., Sionis, A., Zaman, A., & Jukema, J. W. (2023). The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project. Vascul Pharmacol., 148, 107141. Doi: 10.1016/j.vph.2023.107141.
Allahyari, A., Jernberg, T., Hagstro¨m, E., Leosdottir, M., Lundman, P., & Ueda, P. (2020). Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent,myocardial infarction: a simulation study. Eur. Heart J. 41, 3900–3909 Doi:10.1093/eurheartj/ehaa034
Haegele, M., Djurdjevic, A., Jordan, F., Liu, Y.-C., Mildner, L., Frey, S., Strebel, I., Clerc, O., Burkard, T., & Pfister, O. (2022). Achievement of Low-Density Lipoprotein Cholesterol Targets in Cardiac Rehabilitation: Impact of the 2019 ESC/EAS Dyslipidaemia Guidelines. J. Clin. Med., 11, 7057. Doi. 10.3390/jcm11237057
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.